Long title
An open-label, phase I, multi-center study to determine in relapsed/refractory acute myeloid leukemia or myelodysplasic syndrome patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for non-progressive patients.
Date receipt dossier
EU record number
CYAD-02-001
EudraCT number
2019-001816-46
Company / Sponsor
Celyad
Phase
I
Treated organism
Humans
Indication category
Cancer therapy
Disease
Multiple myeloma
Therapeutic approach
Immunotherapy
Genetic modification
NKG2D-chimeric antigen receptor, ShRNA targeting the endogenous RNA of NKG2D ligands MICA and MICB and truncated CD19 reporter protein
Method of transfer of nucleic acid of interest
Moloney murine leukemia virus
Administered biological material
Autologous T-cells retrovirally transduced with a chimeric antigen receptor based on the NKG2D receptor, a ShRNA targeting the endogenous RNA of NKG2D ligands MICA and MICB and a truncated CD19 reporter protein
Route of administration
Intravenous
Locations in Belgium
AZ Delta, CHU Liège, UZ Leuven
Nr of subjects
27
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
CYAD-02